MedTrace Logo

Duration of Protection From Pneumonia After Pneumococcal Vaccination in Hemodialysis Patients

NCT03350425 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 792

Last updated 2024-12-16

No results posted yet for this study

Summary

The investigators compare two strata of vaccinated patients: those recently vaccinated and those vaccinated more than two years ago. The primary objective is to compare pneumonia rates between the groups. As exploratory objectives, the investigators will describe the anti-pneumococcal antibody titers in hemodialysis patients as a function of time since vaccination, and determine factors influencing antibody kinetics. Further exploratory objectives investigate the relationship between antibody titers and the incidence of pneumonia in hemodialysis patients and extrapolate a possible cut-off for protection from pneumonia.

Conditions

  • CKD (Chronic Kidney Disease) Stage 5D
  • Pneumonia

Sponsors & Collaborators

  • German Center for Infection Research

    collaborator OTHER

  • University of Cologne

    lead OTHER

Principal Investigators

  • Oliver A Cornely, MD · University of Cologne

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-21
Primary Completion
2022-12-01
Completion
2022-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03350425 on ClinicalTrials.gov